disease burden

2.

Core provisions largely unchanged in Global Fund’s revised Eligibility Policy

12 May 2018
Biggest change is new metrics and thresholds for determining TB burden

Under the revised Eligibility Policy adopted by the Board, the core provisions remain largely intact. Most of the changes are on the periphery. The revised policy was adopted by the Board at its recent meeting in Skopje, Macedonia. The Board was acting on the recommendations of its Strategy Committee.

3.

Global Fund’s Strategy Committee favors retaining GNI per capita as a measure of country income

16 Nov 2017
Committee believes that emergency funding for ineligible countries should be addressed outside the Eligibility Policy
Revised Eligibility Policy will be submitted to the Board in May 2018

The Strategy Committee, which has been discussing possible changes to the Global Fund’s Eligibility Policy, will recommend a revised strategy to the Board at the its

1.

Global Fund releases information on the 2017-2019 allocations

19 Dec 2016

After informing eligible countries of their 2017-2019 allocations (see GFO article in this issue), the Secretariat posted a spreadsheet on its website showing the full list of allocations.

11.

An Equitable Access Initiative report presents alternatives to the use of income level classification in decisions on eligibility and resource prioritization

19 Dec 2016
Multi-criteria framework recommended

From the perspective of the Global Fund, the main takeaway from the final report of the Equitable Access Initiative (EAI) is that decisions on eligibility and prioritization of resources should be based on more than just income level and disease burden. The EAI recommends that a multi-criteria framework be used instead.

6.

Parameters for the qualitative adjustments for 2017-2019 allocations

15 Dec 2016
Determined by the Strategy Committee in June 2016

Last June, when the Strategy Committee approved the qualitative adjustment process for 2017-2019 allocations (see GFO article), it also approved the parameters that are being used to make the adjustments in Stage 1 (epidemiological considerations) and Stage 2 (holistic adjustment – primarily absorption and impact).

9.

Description of qualitative adjustment process for 2017-2019 allocations

29 Nov 2016
Process was decided by Strategy Committee in June 2016

At first glance, it may appear that the qualitative adjustment process for the 2017-2019 allocations is simpler than the process used for the 2014-2016 allocations. But, in the final analysis, it is probably every bit as complicated.

2.

The Global Fund should align its catalytic investments with global targets for malaria elimination and eradication

7 Jun 2016

In 2015, the World Health Organization (WHO) reported that among the 106 countries with malaria transmission in 2000, more than half had achieved at least a 75% reduction in new cases. The Global Fund’s investments have been, and continue to be, a key driver of this success. Dedicated funding for malaria has dramatically reduced the malaria burden and sustained these reductions.

1.

More is known about the impact of the new allocation methodology

7 Jun 2016
EECA’s allocation will be cut in half; Southern Africa’s share will increase 50%

In April 2016, the Global Fund Board approved a new allocation methodology for the period 2017-2019 (see GFO article).

3.

CSOs call for transition planning in countries facing declines in Global Fund support

14 Jan 2015
Thirty-two components in UMI countries became ineligible for funding in the years leading up to the NFM

The impact on upper-middle-income (UMI) countries of the decision to shift more resources to low-income countries remains the subject of heated and passionate discussions within the Global Fund ecology.

1.

New Aidspan paper looks at cost per notified case in high burden TB countries

29 Oct 2014

Since its inception, the Global Fund has played an increasingly significant role in providing funding for TB control programs in Fund- eligible countries.  By 2012, this contribution made up 80% of all international spending on TB. 

Pages

Subscribe to disease burden